Apimostinel is under clinical development by Gate Neurosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Apimostinel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Apimostinel (NRX-1074, AGN-241660) is under development for the treatment of acute sever major depressive disorder. The drug candidate is administered through intravenous route. NRX-1074, is NMDAR partial agonist. NRX-1074 is based on NMDAR modulation platform, comprising novel patented chemistry classes with key molecular features.
It was also under development for major depressive disorder. It was administered through oral route.
Gate Neurosciences overview
Gate Neurosciences offer neuroscience-related medical services. IT is headquartered in Carmel, Indiana, the US.
For a complete picture of Apimostinel’s drug-specific PTSR and LoA scores, buy the report here.